Search
Onconetix Inc
ONCOAdd to Watchlist
0.374USD
-0.016-4.10%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
4.29MMarket Cap
LossP/E TTM
More Details of Onconetix Inc Company
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Onconetix Inc Info
Ticker SymbolONCO
Company nameOnconetix Inc
IPO dateFeb 18, 2022
CEOFedasz (Karina M)
Number of employees5
Security typeOrdinary Share
Fiscal year-endFeb 18
Address201 E. Fifth Street
CityCINCINNATI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code45202
Phone15136204101
Websitehttps://www.onconetix.com/
Ticker SymbolONCO
IPO dateFeb 18, 2022
CEOFedasz (Karina M)
Company Executives of Onconetix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
132.00
-6.06%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
132.00
-6.06%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q1
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Switzerland
796.59K
97.70%
United Kingdom
18.78K
2.30%
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Altos Venture AG
0.48%
Geode Capital Management, L.L.C.
0.10%
Young (Michael)
0.10%
DRW Securities, LLC
0.07%
HRT Financial LP
0.03%
Other
99.23%
Shareholders
Shareholders
Proportion
Altos Venture AG
0.48%
Geode Capital Management, L.L.C.
0.10%
Young (Michael)
0.10%
DRW Securities, LLC
0.07%
HRT Financial LP
0.03%
Other
99.23%
Shareholder Types
Shareholders
Proportion
Corporation
8.28%
Investment Advisor
2.28%
Individual Investor
1.86%
Investment Advisor/Hedge Fund
1.69%
Venture Capital
0.31%
Hedge Fund
0.05%
Research Firm
0.02%
Other
85.50%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
29
26.70K
3.85%
+2.19K
2025Q4
31
91.66K
5.89%
+62.90K
2025Q3
31
22.38K
5.65%
+17.05K
2025Q2
47
63.91K
38.67%
+44.58K
2025Q1
54
64.94K
25.23%
+43.00K
2024Q4
54
5.57M
44.93%
+3.81M
2024Q3
55
5.45M
45.59%
+5.19M
2024Q2
54
145.05K
20.85%
-52.13K
2024Q1
56
197.34K
30.36%
-46.00
2023Q4
55
198.08K
30.63%
+320.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Altos Venture AG
54.65K
7.89%
+48.30K
+761.52%
Jul 14, 2025
Geode Capital Management, L.L.C.
661.00
0.1%
+661.00
--
Dec 31, 2025
DRW Securities, LLC
7.81K
1.13%
-4.55K
-36.81%
Dec 31, 2025
HRT Financial LP
--
0%
-337.00
-100.00%
Jun 30, 2025
Abante Asesores Gestión, S.G.I.I.C., S.A.
2.94K
0.42%
+2.94K
--
Dec 31, 2025
XTX Markets LLC
2.17K
0.31%
+2.17K
--
Dec 31, 2025
UBS Financial Services, Inc.
1.84K
0.27%
+740.00
+67.21%
Dec 31, 2025
Bruhlmann (Christian)
1.44K
0.21%
--
--
Dec 12, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 23, 2026
Merger
5→1
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Date
Ex-dividend Date
Type
Ratio
Mar 23, 2026
Merger
5→1
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
